158 related articles for article (PubMed ID: 18971013)
1. Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature.
Cigni A; Faedda R; Atzeni MM; Pileri PV; Alagna S; Rovasio P; Satta AE; Loi MR; Sini A; Satta V; Masala A
Am J Kidney Dis; 2008 Nov; 52(5):887-96. PubMed ID: 18971013
[TBL] [Abstract][Full Text] [Related]
2. Use of testosterone to prevent cyclophosphamide-induced azoospermia.
Masala A; Faedda R; Alagna S; Satta A; Chiarelli G; Rovasio PP; Ivaldi R; Taras MS; Lai E; Bartoli E
Ann Intern Med; 1997 Feb; 126(4):292-5. PubMed ID: 9036801
[TBL] [Abstract][Full Text] [Related]
3. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
4. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
5. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
6. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors.
van Casteren NJ; van der Linden GH; Hakvoort-Cammel FG; Hählen K; Dohle GR; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2009 Jan; 52(1):108-12. PubMed ID: 18819129
[TBL] [Abstract][Full Text] [Related]
7. Relationship of serum and seminal plasma zinc levels and serum testosterone in oligospermic and azoospermic infertile men.
Ali H; Baig M; Rana MF; Ali M; Qasim R; Khem AK
J Coll Physicians Surg Pak; 2005 Nov; 15(11):671-3. PubMed ID: 16300697
[TBL] [Abstract][Full Text] [Related]
8. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease.
Dooley MA; Nair R
Nat Clin Pract Rheumatol; 2008 May; 4(5):250-7. PubMed ID: 18364720
[TBL] [Abstract][Full Text] [Related]
9. Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases.
Haubitz M; Ehlerding C; Kamino K; Koch KM; Brunkhorst R
Clin Nephrol; 1998 Jan; 49(1):19-23. PubMed ID: 9491281
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis?
Wetzels JF
Neth J Med; 2004 Nov; 62(10):347-52. PubMed ID: 15683089
[TBL] [Abstract][Full Text] [Related]
11. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
Reh A; Oktem O; Oktay K
Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
[TBL] [Abstract][Full Text] [Related]
12. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
[TBL] [Abstract][Full Text] [Related]
13. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.
Donnez J; Dewart PJ; Hedon B; Perino A; Schindler AE; Blumberg J; Querleu D
Fertil Steril; 2004 Feb; 81(2):297-304. PubMed ID: 14967363
[TBL] [Abstract][Full Text] [Related]
14. Strategies for preservation of ovarian and testicular function after immunosuppression.
Pendse S; Ginsburg E; Singh AK
Am J Kidney Dis; 2004 May; 43(5):772-81. PubMed ID: 15112167
[TBL] [Abstract][Full Text] [Related]
15. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
16. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
[TBL] [Abstract][Full Text] [Related]
17. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg).
Grigg AP; McLachlan R; Zaja J; Szer J
Bone Marrow Transplant; 2000 Nov; 26(10):1089-95. PubMed ID: 11108308
[TBL] [Abstract][Full Text] [Related]
18. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients.
Huser M; Crha I; Ventruba P; Hudecek R; Zakova J; Smardova L; Kral Z; Jarkovsky J
Hum Reprod; 2008 Apr; 23(4):863-8. PubMed ID: 18258763
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of cyclophosphamide in the treatment of proliferative glomerulonephritis.
Koelz AM; Morley AR; Uldall PR; Kerr DN
Proc Eur Dial Transplant Assoc; 1975; 11():491-9. PubMed ID: 1105560
[TBL] [Abstract][Full Text] [Related]
20. [A controlled clinical trial of Consupren versus cyclophosphamide in chronic glomerulonephritis].
Matl I; Matousovic K; Herout V; Konecný K; Kovác A; Rychlík I; Sobotová D; Roland R; Zdichyncová I; Lánská V
Cas Lek Cesk; 1997 Feb; 136(4):120-3. PubMed ID: 9221182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
